Skip to Main Content
An official website of the United States government
Epidemiology and Genomics Research Program

January 2025 EGRP Cancer Epidemiology News

EGRP Cancer Epidemiology News


2024 Year in Review

Message from Associate Director, Epidemiology and Genomics Research Program

Greetings,

As we embark on a new year, I want to take a moment to reflect on 2024 and my first year as Associate Director of the Epidemiology and Genomics Research Program (EGRP). Personally, it has been a time of learning, growth, and collaboration. One of the highlights has undoubtedly been the chance to engage directly with EGRP's grantees and collaborators at various scientific meetings and conferences, including the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network Meeting, the Cohorts for Environmental Exposures and Cancer Risks (CEECR)External Web Site Policy Symposium, the American Society of Cancer Research (AACR)External Web Site Policy Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and Medically Underserved, and the NCI Cohort Consortium Annual Meeting. Another highlight in this new journey has been getting to know EGRP's dedicated team and their commitment to advancing EGRP’s mission. This engagement across the board have been invaluable in broadening my understanding of the groundbreaking research being conducted in EGRP to advance cancer epidemiology and genomics research and the importance of collaboration in driving progress.

It has certainly been a time of progress for the program. In this newsletter, you can read more about some of EGRP’s achievements over the past year, including a new program director in our Genomic Epidemiology Branch, funding opportunities that EGRP staff are scientific contacts for, scientific webinars and meetings that EGRP supported, and updates to research resources that EGRP makes available to the broader scientific community.

May the coming year bring even greater opportunities to further our mission in cancer epidemiology research. On behalf of the entire EGRP team, I hope you and your loved ones had a joyful and peaceful holiday.

Warmest regards,
Erin Siegel

New EGRP Program Director

In April, Sarah Kalia, PhD, SM, ScM, joined EGRP’s Genomic Epidemiology Branch (GEB). Her responsibilities include developing and managing a portfolio of grants that focuses on genetic susceptibility to cancer and issues around the interpretation and reporting of genetic results.

Prior to joining NCI, Dr. Kalia worked in health economics and outcomes research, and she also has prior experience directing research development, managing projects, and working as a genetic counselor in the Genomes2People research program at Brigham and Women’s Hospital. Dr. Kalia has served in several roles for the National Society of Genetic Counselors (NSGC), including as chair of the NSGC Practice Guidelines Committee.

Supporting Research

2024 Year End Chart showing milestones

EGRP’s Grants Portfolio and Funding Opportunities Issued in 2024

EGRP joins with other divisions, offices, and centers at NCI and other NIH institutes to fund investigator-initiated research and applications submitted in response to funding opportunities. EGRP supports projects in the United States and globally. We are happy to report that the overall number of funded projects that EGRP oversees increased in fiscal year 2024 to 346 grants valued at $254 million, including 56 early-stage investigators.

Learn more about EGRP's portfolio as part of the Division of Cancer Control and Population Sciences’ recently released 2024 research portfolio page with interactive graphs and maps. A list of active cancer epidemiology and genomics projects (and sub-projects) funded by EGRP is also available.

Funding Opportunities that EGRP Staff were Involved With

EGRP staff were involved with 20 new funding opportunities in 2024 that are still accepting applications.

  • RFA-MD-24-010, Environmental Health Disparities Centers (P50, Clinical Trial Optional)
  • RFA-DA-25-026, HEAL Initiative: JCOIN Phase II Community Engaged Research Resource Center (U24, Clinical Trial Optional)
  • RFA-NR-24-006, Understanding the Intersection of Social Inequities to Optimize Health and Reduce Health Disparities: The Axes Initiative (R01, Clinical Trial Optional)
  • PAR-25-145, Clinical Characterization of Cancer Therapy-Induced Sequelae and Mechanism-based Interventional Strategies (R01, Clinical Trial Optional)
  • PAR-25-170, Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3, Clinical Trial Optional)
  • PAR-24-304, Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
  • Stephen I. Katz Early Stage Investigator Research Project Grant
    • PAR-24-076 (R01, Basic Experimental Studies with Humans Required)
    • PAR-24-075 (R01, Clinical Trial Not Allowed)
  • PAR-25-292, The Role of Work in Health Disparities in the U.S. (R01, Clinical Trials Optional)
  • PAR-25-109, Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03, Clinical Trial Not Allowed)
  • Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment
  • PAR-25-312, Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk (R01, Clinical Trial Not Allowed)
  • PA-25-253, Exploratory Grants in Cancer Control (R21, Clinical Trial Optional)
  • NOT-CA-25-004, Notice of Special Interest (NOSI): Administrative Supplements for Assessing Capacity to Address Obesity for Cancer Prevention and Control
  • NOT-OD-25-015, NOSI: Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues
  • NOT-CA-24-037, NOSI: Epidemiologic Studies to Assess the Impact of Incretin Mimetics on New and Recurrent Cancer Risk
  • NOT-CA-25-024, NOSI: Survivorship Research for People Living with Advanced and Metastatic Cancers
  • NOT-CA-24-031, NOSI: Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research
  • NOT-CA-25-010, NOSI: Research on Rare Cancers Across the Cancer Control Continuum
  • NOT-CA-24-073, NOSI: Factors Impacting How Time-Restricted Eating (TRE) Influences Cancer-related Outcomes

The following 22 funding announcements that staff were involved with were issued with the new simplified review framework review criteria.*

* Per NOT-OD-24-086, updated application forms (FORMS-I) will be used for these opportunities.

  • Advancing Genomic Medicine Research
  • Biology of Bladder Cancer
  • PAR-25-186, Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01, Clinical Trial Not Allowed)
  • Co-infection and Cancer
  • Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits
  • Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility
  • Exploratory/Developmental Bioengineering Research Grants
  • Impacts of Climate Change across the Cancer Control Continuum
  • PAR-25-299, Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01, Clinical Trials Optional)
  • PA-25-172, Modular R01s in Cancer Control and Population Sciences (R01, Clinical Trial Optional)
  • PAR-25-072, Pragmatic Trials across the Cancer Control Continuum (UG3/UH3, Clinical Trial Required)
  • PAR-25-275, Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01, Clinical Trial Not Allowed)
  • Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes
  • PAR-25-109, Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03, Clinical Trial Not Allowed)

EGRP staff were involved with 3 new funding opportunities in 2024 that are no longer accepting applications.

  • RFA-HG-24-021, Population Genomic Screening in Primary Care Cooperative Agreement (U01, Clinical Trial Required)
  • NOT-CA-24-030, NOSI: Administrative Supplement for Contemporary Modifiable Exposures and Cancer Across the Life Course and Cancer Control Continuum
  • NOT-CA-23-037, NOSI: Technology Development for Cancer Control and Population Science Research

Scientific Meetings and Webinars

In collaboration with other NCI and NIH programs, EGRP staff planned several scientific meetings to bring together experts and interested individuals to collaborate regarding solutions to scientific questions and research needs.

  • EGRP staff organized and participated in the Think Tank on Advancing Gastric Cancer Prevention on May 17, 2024. The aim of the Think Tank was to provide a forum for a multidisciplinary group of gastric cancer experts to review the state of the science and collaboratively identify critical knowledge gaps.
  • Two EGRP staff members were involved in a two-day workshop, Population Descriptors for Legacy Genomic Data: Challenges and Future Directions, on May 28-29, 2024. This workshop brought together leaders of genomic data science resources, researchers who use legacy data, and other partners to make recommendations regarding the application of population descriptors to existing data.
  • EGRP staff members were also involved in two multi-day workshops hosted by the National Collaborative on Childhood Obesity Research (NCCOR): Obesity-Related Policy, Systems, and Environmental Research in the USExternal Web Site Policy (OPUS). OPUS IExternal Web Site Policy, which took place June 4-5, 2024, featured presentations from leading obesity-prevention and public health experts. The workshop examined best practices in obesity prevention research with specific attention to community engagement and systems change through an equity lens. Then on October 9-10, 2024, OPUS IIExternal Web Site Policy focused on the next generation of equity-centered, community-engaged policy, systems, and environmental (PSE) interventions for childhood obesity prevention. This virtual workshop explored critical methodological considerations, innovative research approaches, and practical strategies for evaluating PSE interventions.
  • EGRP staff planned and participated in the Oral Microbiome in Health and Systemic Diseases meeting, which was held on June 25, 2024. Objectives included improving current knowledge of mechanisms of host interactions with the oral microbiome affecting host health and disease, identifying knowledge gaps and research priorities for oral microbiome studies that define mechanisms in both local and distal tissues that contribute to disease development, identifying interventions for modulating oral microbiota for disease interception and risk reduction, and evaluating tools and methodologies for analyzing oral microbiome.
  • An EGRP program director was involved in a workshop, Using AI to Better Understand Menopause, which took place on September 4, 2024. The event aimed to allow researchers from different disciplines to identify gaps in the science and share promising techniques and continuing challenges that could be solved by collaborative research in the future, ultimately resulting in the development of novel teams of women’s health researchers in the United States.
  • EGRP hosted the 2024 NCI Cohort Consortium Annual Meeting from November 12-15, 2024. The goal was to bring together consortium members and other interested researchers to discuss emerging science; ideas for new scientific projects; scientific progress of the consortium’s projects and groups; as well as gaps and opportunities for collaboration across studies.
  • EGRP staff planned and participated in the NIH-FDA Nutrition Regulatory Science WorkshopExternal Web Site Policy, which took place December 17-18, 2024. The goal of this joint NIH-FDA workshop was to highlight how nutrition science can generate evidence and data to inform food-related policy and regulatory decision making and to foster additional collaboration between NIH and FDA in supporting research that addresses priority nutrition research gaps. Some topics that were discussed at the workshop: ultra-processed foods, impact analysis and implementation science related to regulatory actions, and emerging technological innovations related to nutrition regulatory science.

EGRP staff also organized and participated in more than 15 scientific webinars in 2024, most of which have been archived and are available to watch. These webinars were part of ongoing series focused on:

There were also ad hoc webinars, including:

More details about upcoming and past webinars are available on the EGRP events web page.

Updated Research Resources

EGRP supports a number of web-based tools that can be used for research-related purposes. EGRP’s collection of dietary assessment resources was updated in 2024 to include:

Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool

  • ASA24 is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records. Some of the most common uses on ASA24 include epidemiologic, interventional, behavioral, and clinical research. In April 2024, NCI released ASA24-2024, which includes updated food codes and nutrient values, along with new portion size food images for some popular foods. More information about ASA24, including a demo version, is available on EGRP’s website.

Linking ASA24 and NHANES Data with the Nova Classification System for Industrial Food Processing

To learn more about these and other research resources, please visit https://epi.grants.cancer.gov/research-resources/.

Other Funding Opportunities

  • RFA-OD-25-001, High-Priority Research in Tobacco Regulatory Science (R01, Clinical Trial Optional)
  • RFA-HG-25-007, Informatics Tools for the Pangenome (U01, Clinical Trial Not Allowed)
  • RFA-CA-25-001, Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61, Clinical Trial Not Allowed)
  • RFA-CA-25-002, Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
  • RFA-CA-25-003, Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61, Clinical Trial Not Allowed)
  • RFA-CA-25-004, Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
  • RFA-CA-25-019, Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01, Clinical Trial Optional)
  • Exploratory/Developmental Bioengineering Research Grants (EBRG)
  • Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research
  • Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment
  • PAR-25-299, Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01, Clinical Trials Optional)*
  • PAR-25-292, The Role of Work in Health Disparities in the U.S. (R01, Clinical Trials Optional)
  • PAR-25-242, Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33, Clinical Trial Optional)
  • PAR-24-330, Interventions to Reduce Sleep Health Disparities (R01, Clinical Trials Optional)
  • PAR-25-279, New Approaches for Measuring Brain Changes Across Longer Timespans (R01, Clinical Trial Optional)
  • NCI Continuing Umbrella of Research Experiences (CURE)
    • PAR-24-317, Non-Mentored Research Scientist Career Development Award (K22, Independent Clinical Trial Not Allowed)
    • PAR-24-318, Non-Mentored Research Scientist Career Development Award (K22, Clinical Trial Required)
    • PAR-24-319, Mentored Clinical Scientist Research Career Development Award (K08, Clinical Trial Required)
    • PAR-24-320, Mentored Clinical Scientist Research Career Development Award (K08, Clinical Trial Not Allowed)
  • PAR-25-134, Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15, Clinical Trial Not Allowed)
  • PAR-25-317, Risk and Protective Factors of Family Health and Family Level Interventions (R01, Clinical Trial Optional)
  • PAR-25-336, Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01, Clinical Trial Not Allowed)
  • PAR-25-109, Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03, Clinical Trial Not Allowed)
  • PAR-25-312, Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk (R01, Clinical Trial Not Allowed)
  • PAR-22-233, Time-Sensitive Opportunities for Health Research (R61/R33, Clinical Trial Not Allowed)
  • NIH Research Project Grant
    • PA-25-301 (Parent R01, Clinical Trial Not Allowed)
    • PA-25-303 (Parent R01, Basic Experimental Studies with Humans Required)
  • NOT-CA-25-012, Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments
  • NOT-CA-25-006, NOSI: Communication and Decision-Making in a Complex and Dynamic Cancer Treatment Environment
  • NOT-CA-25-024, NOSI: Survivorship Research for People Living with Advanced and Metastatic Cancers
  • NOT-CA-25-010, NOSI: Research on Rare Cancers Across the Cancer Control Continuum
  • NOT-CA-25-002, NOSI: Mechanisms Driving Obesity and Prostate Cancer Risk
  • Notice of Intent to Publish a Funding Opportunity Announcement for Academic Career Excellence (ACE) Award
  • Notice of Intent to Publish a Funding Opportunity Announcement for NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award
* These announcements have been reissued with the new simplified review framework review criteria. Per NOT-OD-24-086 updated application forms (FORMS-I) will be used for this opportunity.

Requests for Information

  • NOT-OD-25-050, Request for Public Comment: NIH Plan to Increase Findability and Transparency of Research Results Through the Use of Metadata and Persistent Identifiers (PIDs) (responses requested by February 21, 2025)
  • NOT-OD-25-038, Inviting Feedback on the Framework for the NIH Strategic Plan for Disability Health Research FY26-FY30 (responses requested by March 12, 2025)

Grants Policy Announcements

  • NOT-OD-25-021, Standard Language for Developer Terms of Access in the Terms and Conditions of Award
  • NOT-OD-25-044, Reminder of Updates to NIH Training Grant Application Data Tables for Application Due Dates on or After January 25, 2025
  • NOT-OD-25-047, 2024 NIH Public Access Policy
  • NOT-OD-25-048, Supplemental Guidance to the 2024 NIH Public Access Policy: Publication Costs
  • NOT-OD-25-049, Supplemental Guidance to the 2024 NIH Public Access Policy: Government Use License and Rights
  • NOT-OD-25-052, Announcing Community Days Webinars on Updated NIH Security Best Practices for Users of Genomic Controlled-Access Data

Reports

News and Blog Posts

Stay Connected

Subscribe for Updates

Subscribe
You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.

Subscribe to the E-Newsletter

Need Help?

EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.

Email Us
(240) 276-6730